Recombinant Human CHREBP protein (GST tag N-Terminus)
Be the first to review this product! Submit a review
|
(1 Publication)
Recombinant Human CHREBP protein (GST tag N-Terminus) is a Human Fragment protein, in the 603 to 700 aa range, expressed in Wheat germ, suitable for ELISA, WB.
View Alternative Names
BHLHD14, MIO, WBSCR14, MLXIPL, Carbohydrate-responsive element-binding protein, ChREBP, Class D basic helix-loop-helix protein 14, MLX interactor, MLX-interacting protein-like, WS basic-helix-loop-helix leucine zipper protein, Williams-Beuren syndrome chromosomal region 14 protein, bHLHd14, WS-bHLH
- SDS-PAGE
Unknown
SDS-PAGE - Recombinant Human CHREBP protein (GST tag N-Terminus) (AB162408)
ab162408 on a 12.5% SDS-PAGE stained with Coomassie Blue.
Reactivity data
Sequence info
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Specifications
Form
Liquid
General info
Function
Glucose-responsive transcription activator that regulates fatty acid synthesis and glycolysis. Key determinant of systemic insulin sensitivity and glucose homeostasis. Important for the expression of fatty acid synthetic enzymes, including PC/Pcx, APOC4/Acl, ACACA/Acc1 and FASN/Fas (By similarity). Important for glucose-induced expression of L-type pyruvate kinase/PKLR (By similarity). Binds to the canonical and non-canonical E box DNA sequences 5'-CACGTG-3' and 5'-CACGCG-3' (By similarity). May also act as a transcriptional repressor (By similarity).
Post-translational modifications
Phosphorylation at Ser-556 by AMPK inactivates the DNA-binding activity.
Subcellular localisation
Nucleus
Target data
Publications (1)
Recent publications for all applications. Explore the full list and refine your search
Metabolites 13: PubMed36837888
2023
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com